MY154898A - P70 s6 kinase inhibitors - Google Patents

P70 s6 kinase inhibitors

Info

Publication number
MY154898A
MY154898A MYPI20094763A MYPI20094763A MY154898A MY 154898 A MY154898 A MY 154898A MY PI20094763 A MYPI20094763 A MY PI20094763A MY PI20094763 A MYPI20094763 A MY PI20094763A MY 154898 A MY154898 A MY 154898A
Authority
MY
Malaysia
Prior art keywords
kinase inhibitors
formula
methods
provides
present
Prior art date
Application number
MYPI20094763A
Other languages
English (en)
Inventor
Dally Robert Dean
Huang Jianping
Joseph Sajan
Shepherd Timothy Alan
Christian L Holst
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY154898A publication Critical patent/MY154898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20094763A 2007-05-11 2008-05-01 P70 s6 kinase inhibitors MY154898A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
MY154898A true MY154898A (en) 2015-08-28

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20094763A MY154898A (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Country Status (33)

Country Link
US (2) US8093383B2 (cg-RX-API-DMAC10.html)
EP (1) EP2148880B1 (cg-RX-API-DMAC10.html)
JP (1) JP5503532B2 (cg-RX-API-DMAC10.html)
KR (1) KR101088219B1 (cg-RX-API-DMAC10.html)
CN (1) CN101679439B (cg-RX-API-DMAC10.html)
AR (1) AR066344A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008251692B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0811212A2 (cg-RX-API-DMAC10.html)
CA (1) CA2687265C (cg-RX-API-DMAC10.html)
CL (1) CL2008001230A1 (cg-RX-API-DMAC10.html)
CO (1) CO6241109A2 (cg-RX-API-DMAC10.html)
CR (1) CR11106A (cg-RX-API-DMAC10.html)
DK (1) DK2148880T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2009000257A (cg-RX-API-DMAC10.html)
EA (1) EA016445B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099721A (cg-RX-API-DMAC10.html)
ES (1) ES2483726T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900292A (cg-RX-API-DMAC10.html)
HR (1) HRP20140611T1 (cg-RX-API-DMAC10.html)
IL (1) IL201564A (cg-RX-API-DMAC10.html)
MA (1) MA31433B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009012075A (cg-RX-API-DMAC10.html)
MY (1) MY154898A (cg-RX-API-DMAC10.html)
NZ (1) NZ580423A (cg-RX-API-DMAC10.html)
PE (1) PE20090887A1 (cg-RX-API-DMAC10.html)
PL (1) PL2148880T3 (cg-RX-API-DMAC10.html)
PT (1) PT2148880E (cg-RX-API-DMAC10.html)
RS (1) RS53451B (cg-RX-API-DMAC10.html)
SI (1) SI2148880T1 (cg-RX-API-DMAC10.html)
TN (1) TN2009000446A1 (cg-RX-API-DMAC10.html)
TW (1) TWI423805B (cg-RX-API-DMAC10.html)
UA (1) UA99284C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008140947A1 (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
AU2009314336B2 (en) 2008-11-11 2013-09-12 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
EA020302B1 (ru) 2009-08-07 2014-10-30 Мерк Патент Гмбх Новые азагетероциклические соединения
ES2465094T3 (es) 2009-10-23 2014-06-05 Eli Lilly And Company Inhibidores de AKT
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
KR101894116B1 (ko) 2010-11-24 2018-08-31 메르크 파텐트 게엠베하 퀴나졸린 카르복사미드 아제티딘
EP2755965B1 (en) * 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX2015002887A (es) * 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2890345A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2620119T3 (es) 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
HK1218756A1 (zh) 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2015240094B2 (en) 2014-04-03 2020-07-30 Merck Patent Gmbh Combinations of cancer therapeutics
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
EP4243819A1 (en) 2020-11-16 2023-09-20 Merck Patent GmbH Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
CO6241109A2 (es) 2011-01-20
UA99284C2 (ru) 2012-08-10
TW200848053A (en) 2008-12-16
CN101679439B (zh) 2013-09-11
SI2148880T1 (sl) 2014-07-31
ECSP099721A (es) 2009-12-28
BRPI0811212A2 (pt) 2014-10-29
TWI423805B (zh) 2014-01-21
AU2008251692B2 (en) 2012-10-11
RS53451B (sr) 2014-12-31
WO2008140947A1 (en) 2008-11-20
EA016445B1 (ru) 2012-05-30
HRP20140611T1 (hr) 2014-08-15
ES2483726T3 (es) 2014-08-07
CN101679439A (zh) 2010-03-24
KR101088219B1 (ko) 2011-11-30
TN2009000446A1 (en) 2011-03-31
MX2009012075A (es) 2009-11-19
CR11106A (es) 2010-04-12
PT2148880E (pt) 2014-08-28
JP2010526814A (ja) 2010-08-05
DOP2009000257A (es) 2010-03-31
DK2148880T3 (da) 2014-06-16
AU2008251692A1 (en) 2008-11-20
EP2148880A1 (en) 2010-02-03
CA2687265C (en) 2012-12-04
HK1140767A1 (en) 2010-10-22
US20120071490A1 (en) 2012-03-22
JP5503532B2 (ja) 2014-05-28
GT200900292A (es) 2011-06-24
IL201564A0 (en) 2010-05-31
US8093383B2 (en) 2012-01-10
NZ580423A (en) 2012-02-24
AR066344A1 (es) 2009-08-12
MA31433B1 (fr) 2010-06-01
EA200971051A1 (ru) 2010-06-30
IL201564A (en) 2014-08-31
EP2148880B1 (en) 2014-05-28
CA2687265A1 (en) 2008-11-20
CL2008001230A1 (es) 2009-05-22
PE20090887A1 (es) 2009-07-13
US20090163714A1 (en) 2009-06-25
KR20100005710A (ko) 2010-01-15
PL2148880T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
TN2009000446A1 (en) P70 s6 kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MY148634A (en) Pyridazinone derivatives
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
MX2012004780A (es) Inhibidores de akt.
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
MY153915A (en) Organic compounds
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
TNSN08191A1 (en) Kinase inhibitors
PL2079446T3 (pl) Preparat paliperidonu o przedłużonym uwalnianiu
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
MX2008001538A (es) Aril piridinas y metodos para su uso.
UA85505C2 (en) Kinase inhibitors
MX2012011382A (es) Nuevo polimero.
EA201171414A1 (ru) Ингибиторы белков семейства iap